drugset
drugset / Trial / NCT07436741

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

NCT07436741 ↗

Phase 3 Recruiting 106 enrolled Tianjin Medical University Cancer Institute and Hospital
RandomizedParallel-groupSingle-blindTreatment

Summary

To explore the efficacy and safety of surufatinib in combination with AG regimen verus AG regimen as peri-operative treatment in high - risk resectable or borderline resectable pancreatic cancer

Timeline

Start
2026-03-03
Primary completion
2028-09
Completion
2030-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Surufatinib Small molecule 250 mg Oral
Background Capecitabine Small molecule 1650 mg/m2 Oral
Background Capecitabine Small molecule 2000 mg/m2 Oral
Background Gemcitabine Small molecule 1000 unknown Intravenous
Background Paclitaxel Small molecule 125 mg/m2 Intravenous

Indications

malignant pancreatic neoplasm